Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
Clinical trial NCT06118658 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06118658
- Sponsor
- China Medical University, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-01
- Primary completion
- 2025-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.